Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 10/20 | 0.56 |
| ▸ | SYK | P43405 | 10/20 | 0.56 |
| ▸ | CDK2 | P24941 | 10/20 | 0.56 |
| ▸ | SRC | P12931 | 8/20 | 0.56 |
| ▸ | CDK4 | P11802 | 6/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | CDK1 | P06493 | 2/20 | 0.46 |
| ▸ | CDK7 | P50613 | 2/20 | 0.46 |
| ▸ | CDK9 | P50750 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL141036 | 0.82 | CDK2 (0.53) | ZAP70SYKCDK2SRCCDK4 | |
| SCHEMBL146914 | 0.81 | CDK2 (0.52) | ZAP70SYKCDK2SRCCDK4 | |
| SCHEMBL12423148 | 0.77 | ZAP70 (0.61) | ZAP70SYKCDK2SRCCDK4 | |
| SCHEMBL144714 | 0.77 | SYK (0.64) | ZAP70SYKCDK2SRCCDK4 | |
| SCHEMBL14216198 | 0.75 | ZAP70 (0.77) | ZAP70SYKCDK2SRCCDK4 | |
| SCHEMBL14216203 | 0.75 | SYK (0.77) | ZAP70SYKCDK2SRCCDK4 | |
| SCHEMBL14216119 | 0.72 | SYK (0.77) | ZAP70SYKCDK2SRCCDK4 | |
| SCHEMBL14216294 | 0.72 | SYK (0.77) | ZAP70SYKCDK2SRCCDK4 | |
| SCHEMBL14216081 | 0.72 | ZAP70 (0.88) | ZAP70SYKCDK2SRCCDK4 | |
| SCHEMBL14216016 | 0.72 | ZAP70 (0.72) | ZAP70SYKCDK2SRCCDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040181066-A1 | Tyrosine kinase inhibitors | FRALEY MARK E (US) | 2004-09-16 | — | — | US | claimed |
| WO-2003011838-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | claimed |
| US-20140221455-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | Verva Pharmaceuticals, Inc. (AU) | 2014-08-07 | — | — | US | disclosed |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
| WO-2005065686-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) | 2005-07-21 | — | — | WO | disclosed |
| US-20040181066-A1 | Tyrosine kinase inhibitors | FRALEY MARK E (US) | 2004-09-16 | — | — | US | disclosed |
| WO-2003011838-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | ZAP70 4335/4885SYK 4711/4885CDK2 2042/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | ZAP70 4335/4885SYK 4711/4885CDK2 2042/4885 |
| US-20040181066-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | ZAP70 151/4885SYK 69/4885CDK2 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.